文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

恶性胸膜间皮瘤的晚期和复发性免疫治疗。

Immunotherapy for advanced and recurrent malignant pleural mesothelioma.

机构信息

Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark.

Digestive Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Brussels, Belgium.

出版信息

Cochrane Database Syst Rev. 2024 Sep 18;9(9):CD014720. doi: 10.1002/14651858.CD014720.

DOI:10.1002/14651858.CD014720
PMID:39291744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11409431/
Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of immune checkpoint inhibitors (single-agent or combination therapy) in people with advanced malignant pleural mesothelioma in a first-line or salvage setting.

摘要

这是一篇 Cochrane 综述（干预措施）的方案。其目的如下：评估免疫检查点抑制剂（单药或联合治疗）在一线或挽救治疗中晚期恶性胸膜间皮瘤患者中的疗效。

相似文献

[1]
Immunotherapy for advanced and recurrent malignant pleural mesothelioma.

Cochrane Database Syst Rev. 2024-9-18

[2]
Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges.

Expert Rev Anticancer Ther. 2016-7

[3]
Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies.

Int J Mol Sci. 2024-10-9

[4]
First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?

Lung Cancer. 2024-8

[5]
Is there a role for immunotherapy in malignant pleural mesothelioma?

Med Oncol. 2018-5-29

[6]
Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.

Am J Respir Cell Mol Biol. 2014-5

[7]
Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.

PLoS One. 2024

[8]
Management of recurrence after initial surgery for malignant pleural mesothelioma: a mini-review.

Future Oncol. 2015

[9]
CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.

Clin Lung Cancer. 2021-3

[10]
Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy.

Clin Respir J. 2019-5

引用本文的文献

[1]
Pleural mesothelioma patients and ex-exposed asbestos workers are immunologically poor responders to oncogenic Merkel cell polyomavirus.

Transl Lung Cancer Res. 2025-7-31

本文引用的文献

[1]
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial.

Lancet Respir Med. 2024-6

[2]
ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis.

BMJ. 2023-11-20

[3]
Global, regional, and national trends in mesothelioma burden from 1990 to 2019 and the predictions for the next two decades.

SSM Popul Health. 2023-6-3

[4]
Assessment of Global Trends in the Diagnosis of Mesothelioma From 1990 to 2017.

JAMA Netw Open. 2021-8-2

[5]
Controversies in the role of radiotherapy in pleural mesothelioma.

Transl Lung Cancer Res. 2021-4

[6]
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.

Cochrane Database Syst Rev. 2021-4-30

[7]
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

CA Cancer J Clin. 2021-5

[8]
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.

Lancet. 2021-1-30

[9]
CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.

Clin Lung Cancer. 2021-3

[10]
Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma.

Ther Adv Med Oncol. 2020-11-12

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索